D
CRISPR Therapeutics AG
CRSP
$43.09
-$2.45-5.37%
D
Sell
5/7/2024Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to D- from E+ on 5/7/2024 due to an increase in the valuation index.
CRISPR Therapeutics AG (CRSP) was upgraded to D- from E+ on 5/7/2024 due to an increase in the valuation index.
E
Sell
4/19/2024Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to E+ from D- on 4/19/2024 due to a decline in the volatility index and valuation index.
CRISPR Therapeutics AG (CRSP) was downgraded to E+ from D- on 4/19/2024 due to a decline in the volatility index and valuation index.
D
Sell
8/8/2023Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to D- from D on 8/8/2023 due to a large decline in the efficiency index, valuation index and total return index. Net income declined 46.5% from -$53.07M to -$77.74M, and total capital declined 1.62% from $2.1B to $2.06B.
CRISPR Therapeutics AG (CRSP) was downgraded to D- from D on 8/8/2023 due to a large decline in the efficiency index, valuation index and total return index. Net income declined 46.5% from -$53.07M to -$77.74M, and total capital declined 1.62% from $2.1B to $2.06B.
D
Sell
7/12/2023Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to D from D- on 7/12/2023 due to an increase in the volatility index, total return index and valuation index.
CRISPR Therapeutics AG (CRSP) was upgraded to D from D- on 7/12/2023 due to an increase in the volatility index, total return index and valuation index.
D
Sell
6/27/2023Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to D- from D on 6/27/2023 due to a decline in the volatility index, total return index and valuation index.
CRISPR Therapeutics AG (CRSP) was downgraded to D- from D on 6/27/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
5/8/2023Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to D from D- on 5/8/2023 due to an increase in the total return index.
CRISPR Therapeutics AG (CRSP) was upgraded to D from D- on 5/8/2023 due to an increase in the total return index.
D
Sell
2/23/2023Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to D- from D on 2/23/2023 due to a noticeable decline in the total return index, growth index and volatility index. Total revenue declined 93.62% from $94 to $6, and operating cash flow declined 7.71% from -$105.22M to -$113.33M.
CRISPR Therapeutics AG (CRSP) was downgraded to D- from D on 2/23/2023 due to a noticeable decline in the total return index, growth index and volatility index. Total revenue declined 93.62% from $94 to $6, and operating cash flow declined 7.71% from -$105.22M to -$113.33M.
D
Sell
8/9/2022Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to D from C on 8/9/2022 due to a significant decline in the valuation index, growth index and efficiency index. Total revenue declined 83.19% from $940 to $158, total capital declined 6.06% from $2.48B to $2.33B, and operating cash flow declined 4.97% from -$135.24M to -$141.96M.
CRISPR Therapeutics AG (CRSP) was downgraded to D from C on 8/9/2022 due to a significant decline in the valuation index, growth index and efficiency index. Total revenue declined 83.19% from $940 to $158, total capital declined 6.06% from $2.48B to $2.33B, and operating cash flow declined 4.97% from -$135.24M to -$141.96M.
C
Hold
7/6/2022Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to C from C- on 7/6/2022 due to an increase in the volatility index.
CRISPR Therapeutics AG (CRSP) was upgraded to C from C- on 7/6/2022 due to an increase in the volatility index.
C
Hold
5/10/2022Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to C- from C on 5/10/2022 due to a major decline in the growth index, volatility index and efficiency index. Total revenue declined 92.71% from $12.9M to $940, operating cash flow declined 57.19% from -$86.04M to -$135.24M, and net income declined 26.88% from -$141.25M to -$179.22M.
CRISPR Therapeutics AG (CRSP) was downgraded to C- from C on 5/10/2022 due to a major decline in the growth index, volatility index and efficiency index. Total revenue declined 92.71% from $12.9M to $940, operating cash flow declined 57.19% from -$86.04M to -$135.24M, and net income declined 26.88% from -$141.25M to -$179.22M.
C
Hold
2/23/2022Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to C from C- on 2/23/2022 due to a significant increase in the growth index and valuation index. Total revenue increased 1,465.41% from $824 to $12.9M.
CRISPR Therapeutics AG (CRSP) was upgraded to C from C- on 2/23/2022 due to a significant increase in the growth index and valuation index. Total revenue increased 1,465.41% from $824 to $12.9M.
C
Hold
11/8/2021Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to C- from C on 11/8/2021 due to a significant decline in the growth index, solvency index and total return index. Earnings per share declined from $9.44 to -$1.67, EBIT declined 116.9% from $762.62M to -$128.85M, and operating cash flow declined 110.08% from $807M to -$81.33M.
CRISPR Therapeutics AG (CRSP) was downgraded to C- from C on 11/8/2021 due to a significant decline in the growth index, solvency index and total return index. Earnings per share declined from $9.44 to -$1.67, EBIT declined 116.9% from $762.62M to -$128.85M, and operating cash flow declined 110.08% from $807M to -$81.33M.
C
Hold
8/31/2021Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to C from C+ on 8/31/2021 due to a decline in the total return index.
CRISPR Therapeutics AG (CRSP) was downgraded to C from C+ on 8/31/2021 due to a decline in the total return index.
C
Hold
8/16/2021Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to C+ from C on 8/16/2021 due to an increase in the total return index.
CRISPR Therapeutics AG (CRSP) was upgraded to C+ from C on 8/16/2021 due to an increase in the total return index.
C
Hold
7/30/2021Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to C from D on 7/30/2021 due to a significant increase in the growth index, valuation index and efficiency index. Total revenue increased 167,005.94% from $539 to $900.7M, operating cash flow increased 901.69% from -$100.66M to $807M, and net income increased 770.91% from -$113.16M to $759.23M.
CRISPR Therapeutics AG (CRSP) was upgraded to C from D on 7/30/2021 due to a significant increase in the growth index, valuation index and efficiency index. Total revenue increased 167,005.94% from $539 to $900.7M, operating cash flow increased 901.69% from -$100.66M to $807M, and net income increased 770.91% from -$113.16M to $759.23M.
D
Sell
3/5/2021Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to D from D+ on 3/5/2021 due to a significant decline in the total return index.
CRISPR Therapeutics AG (CRSP) was downgraded to D from D+ on 3/5/2021 due to a significant decline in the total return index.
D
Sell
2/18/2021Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to D+ from D on 2/18/2021 due to a large increase in the efficiency index, total return index and volatility index. Total capital increased 23.92% from $1.39B to $1.73B.
CRISPR Therapeutics AG (CRSP) was upgraded to D+ from D on 2/18/2021 due to a large increase in the efficiency index, total return index and volatility index. Total capital increased 23.92% from $1.39B to $1.73B.
D
Sell
10/29/2020Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to D from C- on 10/29/2020 due to a significant decline in the efficiency index and valuation index. Net income declined 16.05% from -$79.66M to -$92.44M.
CRISPR Therapeutics AG (CRSP) was downgraded to D from C- on 10/29/2020 due to a significant decline in the efficiency index and valuation index. Net income declined 16.05% from -$79.66M to -$92.44M.
C
Hold
7/21/2020Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to C- from D+ on 7/21/2020 due to a substantial increase in the total return index and volatility index.
CRISPR Therapeutics AG (CRSP) was upgraded to C- from D+ on 7/21/2020 due to a substantial increase in the total return index and volatility index.
D
Sell
6/24/2020Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to D+ from D on 6/24/2020 due to an increase in the total return index and volatility index.
CRISPR Therapeutics AG (CRSP) was upgraded to D+ from D on 6/24/2020 due to an increase in the total return index and volatility index.
D
Sell
5/21/2020Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to D from D+ on 5/21/2020 due to a large decline in the valuation index, total return index and growth index. Operating cash flow declined 1,645.47% from $3.38M to -$52.18M, EBIT declined 770% from $10.98M to -$73.59M, and earnings per share declined from $0.5035 to -$1.146.
CRISPR Therapeutics AG (CRSP) was downgraded to D from D+ on 5/21/2020 due to a large decline in the valuation index, total return index and growth index. Operating cash flow declined 1,645.47% from $3.38M to -$52.18M, EBIT declined 770% from $10.98M to -$73.59M, and earnings per share declined from $0.5035 to -$1.146.
D
Sell
3/26/2020Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to D+ from C- on 3/26/2020 due to a major decline in the growth index, total return index and volatility index. Operating cash flow declined 97.47% from $133.42M to $3.38M, EBIT declined 92.11% from $139.16M to $10.98M, and earnings per share declined from $2.4 to $0.5035.
CRISPR Therapeutics AG (CRSP) was downgraded to D+ from C- on 3/26/2020 due to a major decline in the growth index, total return index and volatility index. Operating cash flow declined 97.47% from $133.42M to $3.38M, EBIT declined 92.11% from $139.16M to $10.98M, and earnings per share declined from $2.4 to $0.5035.
C
Hold
11/6/2019Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to C- from D+ on 11/6/2019 due to an increase in the total return index.
CRISPR Therapeutics AG (CRSP) was upgraded to C- from D+ on 11/6/2019 due to an increase in the total return index.
D
Sell
10/30/2019Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to D+ from D on 10/30/2019 due to a large increase in the growth index, efficiency index and valuation index. Total revenue increased 66,544.03% from $318 to $211.93M, operating cash flow increased 466.72% from -$36.38M to $133.42M, and net income increased 357.78% from -$53.7M to $138.42M.
CRISPR Therapeutics AG (CRSP) was upgraded to D+ from D on 10/30/2019 due to a large increase in the growth index, efficiency index and valuation index. Total revenue increased 66,544.03% from $318 to $211.93M, operating cash flow increased 466.72% from -$36.38M to $133.42M, and net income increased 357.78% from -$53.7M to $138.42M.
D
Sell
8/30/2018Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to D from D+ on 8/30/2018 due to a decline in the total return index, solvency index and efficiency index. Net income declined 35.62% from -$28.3M to -$38.38M, the quick ratio declined from 23.83 to 17.35, and total capital declined 8.67% from $290.34M to $265.15M.
CRISPR Therapeutics AG (CRSP) was downgraded to D from D+ on 8/30/2018 due to a decline in the total return index, solvency index and efficiency index. Net income declined 35.62% from -$28.3M to -$38.38M, the quick ratio declined from 23.83 to 17.35, and total capital declined 8.67% from $290.34M to $265.15M.
D
Sell
7/27/2018Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to D+ from C- on 7/27/2018 due to a noticeable decline in the total return index and volatility index.
CRISPR Therapeutics AG (CRSP) was downgraded to D+ from C- on 7/27/2018 due to a noticeable decline in the total return index and volatility index.
C
Hold
5/29/2018Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to C- from D+ on 5/29/2018 due to a large increase in the solvency index, total return index and volatility index. The quick ratio increased from 16.7 to 23.83.
CRISPR Therapeutics AG (CRSP) was upgraded to C- from D+ on 5/29/2018 due to a large increase in the solvency index, total return index and volatility index. The quick ratio increased from 16.7 to 23.83.
D
Sell
2/26/2018Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to D+ from D on 2/26/2018 due to an increase in the total return index.
CRISPR Therapeutics AG (CRSP) was upgraded to D+ from D on 2/26/2018 due to an increase in the total return index.
D
Sell
2/9/2018Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to D from D+ on 2/9/2018 due to a decline in the volatility index and valuation index.
CRISPR Therapeutics AG (CRSP) was downgraded to D from D+ on 2/9/2018 due to a decline in the volatility index and valuation index.
D
Sell
1/25/2018Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to D+ from D on 1/25/2018 due to a large increase in the total return index, growth index and volatility index. Operating cash flow increased 0.67% from -$15.98M to -$15.87M.
CRISPR Therapeutics AG (CRSP) was upgraded to D+ from D on 1/25/2018 due to a large increase in the total return index, growth index and volatility index. Operating cash flow increased 0.67% from -$15.98M to -$15.87M.
D
Sell
11/1/2017Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to D from D- on 11/1/2017 due to an increase in the volatility index and total return index.
CRISPR Therapeutics AG (CRSP) was upgraded to D from D- on 11/1/2017 due to an increase in the volatility index and total return index.
D
Sell
7/5/2017Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to D- from E on 07/05/2017.
CRISPR Therapeutics AG (CRSP) was upgraded to D- from E on 07/05/2017.
E
Sell
5/30/2017Downgrade
CRISPR Therapeutics AG (CRSP) was downgraded to E from E+ on 5/30/2017 due to a substantial decline in the volatility index, total return index and efficiency index. Net income declined 225.59% from $17.1M to -$21.48M, and total capital declined 7.59% from $232.85M to $215.18M.
CRISPR Therapeutics AG (CRSP) was downgraded to E from E+ on 5/30/2017 due to a substantial decline in the volatility index, total return index and efficiency index. Net income declined 225.59% from $17.1M to -$21.48M, and total capital declined 7.59% from $232.85M to $215.18M.
E
Sell
4/3/2017Upgraded
CRISPR Therapeutics AG (CRSP) was upgraded to E+ from E on 4/3/2017 due to a substantial increase in the total return index, solvency index and growth index. The quick ratio increased from 2.95 to 14.49, earnings per share increased from -$2.7738 to $0.4887, and total revenue increased 51.32% from $1.55M to $2.34M.
CRISPR Therapeutics AG (CRSP) was upgraded to E+ from E on 4/3/2017 due to a substantial increase in the total return index, solvency index and growth index. The quick ratio increased from 2.95 to 14.49, earnings per share increased from -$2.7738 to $0.4887, and total revenue increased 51.32% from $1.55M to $2.34M.
E
Sell
1/13/2017None
CRISPR Therapeutics AG (CRSP) was downgraded to E from U on 01/13/2017.
CRISPR Therapeutics AG (CRSP) was downgraded to E from U on 01/13/2017.
NASDAQ
03/10/2025 1:13PM Eastern
Quotes delayed
